The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.
Andreas Seeber
No relevant relationships to disclose
Ioana Braicu
No relevant relationships to disclose
Gerold Untergasser
No relevant relationships to disclose
Mani Nassir
No relevant relationships to disclose
Normann Steiner
No relevant relationships to disclose
Dominic Fong
No relevant relationships to disclose
Laura Botta
No relevant relationships to disclose
Guenther Gastl
No relevant relationships to disclose
Heidi Fiegl
No relevant relationships to disclose
Alain G Zeimet
No relevant relationships to disclose
Agnieszka Martowicz
No relevant relationships to disclose
Jalid Sehouli
No relevant relationships to disclose
Gilbert Spizzo
Consultant or Advisory Role - Fresenius Biotech (U)